Sander has been working to complete his Phd in the Page Lab since early 2017. Sander's work is focused on characterizing a novel class of compounds that inhibit STAT3 signaling in cancer cells. We are working to uncover the direct molecular target of these compounds and to understand the underlying biological pathways that lead to inhibition of STAT3 signaling.
Drug Discovery and Development
2015 - Current
PhD Candidate, Grander and Page Labs
Karolinska Institute, Stockholm, Sweden
Oncology and Pathology